Key Highlights
- Jaguar Health shares closed down 23% at $1.03.
- Subsidiary Napo Pharmaceuticals supplied a proprietary oral crofelemer formulation for compassionate use.
- The medication is being administered to an infant in the EU for intestinal failure tied to microvillus inclusion disease (MVID).
- The disclosed information does not specify a reason for the share price decline beyond this announcement.
Jaguar Health (NASDAQ: JAGX) shares closed down 23% at $1.03 after the company disclosed that its subsidiary, Napo Pharmaceuticals, has supplied a proprietary oral solution formulation of crofelemer for compassionate use.
What Happened
The medication is being administered to an infant within the EU to manage intestinal failure associated with microvillus inclusion disease (MVID), a rare and serious congenital condition affecting the intestines.
Compassionate use programs typically allow a single patient or a small number of patients to access an otherwise unapproved formulation or indication of a drug on a case-by-case basis, distinct from a broader clinical trial or a full regulatory approval for the indication in question.
MVID is classified as an ultra-rare disease, meaning the total addressable patient population for any therapy targeting the condition specifically is inherently small, a factor that likely limits the direct commercial significance of this particular compassionate use case even as it may carry scientific or reputational value for the company.
Market Reaction
Shares fell 23% despite the compassionate use disclosure, a decline that stands in contrast to the generally positive framing of expanded access programs for a company's therapies.
The scale of the decline suggests investors may be reacting to factors beyond the compassionate use announcement itself, since single-patient expanded access programs typically carry limited direct financial materiality for a company's overall business, unlike a broader regulatory approval or new clinical trial initiation.
Without further disclosed detail, it is difficult to attribute the share price decline directly to the compassionate use news, and the drop may reflect broader company-specific or sector-wide dynamics not captured in the available information.
Jaguar Health has historically positioned crofelemer, marketed commercially as Mytesi for HIV-related diarrhea, as a platform technology with potential applicability across multiple gastrointestinal conditions. Today's compassionate use disclosure in a rare pediatric condition represents one such expansion attempt, though the financial contribution from a single-patient use case is inherently limited compared with a broader approved indication.
Outlook
The disclosed information does not include additional detail on broader commercial or regulatory plans for crofelemer beyond this individual compassionate use case.
Investors are likely to watch for whether this compassionate use case generates additional clinical data that could support broader regulatory applications for crofelemer in MVID or related intestinal failure conditions going forward.
What did Jaguar Health disclose about its subsidiary Napo Pharmaceuticals?
Napo Pharmaceuticals supplied a proprietary oral crofelemer formulation for compassionate use in an infant within the EU with microvillus inclusion disease.
Why did Jaguar Health shares fall 23%?
The disclosed information does not specify a reason for the decline beyond the compassionate use announcement.
What condition is the medication being used to treat?
Intestinal failure associated with microvillus inclusion disease (MVID).


_11_19_2026_08_23_11_186799.jpg)



Please wait processing your request...